Navigation Links
Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch
Date:9/7/2011

leosides.  Setrobuvir has a well-characterized safety database in which more than 350 subjects have received the agent to date.  Anadys was granted U.S. Patent No. 7,939,524, which recognizes the Company's intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds. Setrobuvir has also received Fast Track Status from the FDA for the treatment of chronic hepatitis C or HCV.

Setrobuvir is currently in Phase IIb testing in combination with pegylated interferon and ribavirin for the treatment of HCV.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  All patients are scheduled to complete their 12 week visit by the end of the third quarter of 2011 and the Company expects to release preliminary 12 week data shortly thereafter.  Antiviral response data through 24 weeks are expected around year-end.  

In the second quarter this year, Anadys announced a cross-company clinical trial agreement with a large, commercial-stage biopharmaceutical company to study setrobuvir in combination with another DAA in healthy volunteers.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of setrobuvir (ANA598), the Company's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is  also developing ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C and plans to initiate a Phase IIa study shortly.

S
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598)
2. Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
3. Anadys Pharmaceuticals Appoints Barry Labinger to Its Board of Directors
4. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
5. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
6. Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference
7. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
9. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
11. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ... ... ... ...
... ... ... , ... , , , , ...
Cached Medicine Technology:Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 2Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 3Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 4Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 5Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 6Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 7Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 8Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 9Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 10Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 11Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 12Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 13Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 14Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 15Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 16Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results 17FDA Provides 510k Clearance for BARRX Medical's HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE) 2FDA Provides 510k Clearance for BARRX Medical's HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE) 3FDA Provides 510k Clearance for BARRX Medical's HALO90 Ablation Catheter for the Treatment of Radiation Proctitis and Gastric Antral Vascular Ectasia (GAVE) 4
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... Researchers at the University of California, San Diego School ... those who have suffered a recent major loss are ... older adults. , The study is published in this ... Psychiatry . , Because compassionate behaviors are associated with ... findings offer insights into ways to improve the outcomes ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... rates began to rise again around 2000, researchers have been ... especially in the homosexual community. The rising numbers are a ... to increased awareness of the virus. A new study in ... each year in the last decade saw a startling increase ...
... clinicians with expertise in polypharmacy, caregiving and more ... a free conference examining Alzheimer,s disease. The ... join with the Greater Kentucky and Southern Indiana ... Journey: Alzheimer,s Disease and Caregiving" from 9 a.m. ...
... Steven Reinberg HealthDay Reporter , WEDNESDAY, Aug. 24 ... they have found changes in the chemistry of the brains ... at future risk for Alzheimer,s disease and other dementias. ... the disease, experts say finding ways to identify those at ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- Since 2010, ... available at all has risen dramatically, according to the U.S. ... drugs given by injection and used in hospitals to treat ... are putting patients at risk and compromising their care, experts ...
... The Food and Drug Administration has cleared a new ... of thousands of AIDS patients stricken with cryptococcosis, a fungal ... Kozel, professor of microbiology of the University of Nevada School ... (Immuno-Mycologics) of Oklahoma. The new, rapid blood test known ...
... of HIV have increased in Pakistan,s general population, ... to women and their children, according to an ... Florida scientist. The researchers raise concern that ... may serve as indication that the virus may ...
Cached Medicine News:Health News:Why HIV infection rates are on the rise 2Health News:UofL experts featured at free Alzheimer's disease conference Sept. 17 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 2Health News:Sophisticated Scan May Spot Seeds of Alzheimer's Risk 3Health News:Cancer Drug Shortages Getting Worse, FDA Says 2Health News:Cancer Drug Shortages Getting Worse, FDA Says 3Health News:FDA clears new IMMY and University of Nevada, Reno life-saving blood test 2Health News:Study of HIV increase in Pakistan could benefit other research 2
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
... MiniPrep series of robotic workstations is designed ... MiniPrep is the ideal automation platform for ... routine laboratory procedures, improving throughput, process consistency ... for MiniPrep software allows you to control ...
... for fast, accurate filling of 96 or 384 ... dispensing mechanism, ensures that no liquid can enter ... come into contact with the liquid path are ... compact design saves valuable bench space and allows ...
Medicine Products: